Alterity Therapeutics: Nearing Phase 3 Kickoff, Stock Set to Rise
AI Prediction of Alterity Therapeutics Limited American Depositary Shares (ATHE)
Alterity Therapeutics, a clinical-stage biotech company, is poised for significant advancements with its lead asset ATH434 targeting Multiple System Atrophy (MSA). Positive Phase 2 results and ongoing regulatory discussions are key catalysts.
Alterity Therapeutics is focused on developing ATH434, a promising treatment for Multiple System Atrophy (MSA), a rare neurodegenerative disorder. The company has reported positive Phase 2 results and is advancing towards a pivotal Phase 3 trial. With ATH434 not yet approved and further FDA alignment needed, the stock's movement is likely tied to clinical and regulatory advancements. The upcoming End-of-Phase-2 meeting and potential initiation of Phase 3 trials serve as critical near-term catalysts that could significantly impact the company's valuation and stock price.
ATHE Report Information
Prediction Date2026-03-30
Close @ Prediction$3.16
Mkt Cap60m
IPO Date1992-03-04
AI-derived Information
Recent News for ATHE
- Mar 30, 7:25 am — Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program (GlobeNewswire)
- Mar 9, 7:25 am — Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit (GlobeNewswire)
- Mar 4, 7:25 am — Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor (GlobeNewswire)
- Mar 2, 7:25 am — Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments (GlobeNewswire)
- Jan 30, 7:25 am — Alterity Therapeutics: Appendix 4C - Q2 FY26 Quarterly Cash Flow Report & Corporate Update (GlobeNewswire)
- Jan 21, 7:25 am — Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026 (GlobeNewswire)
- Nov 12, 7:25 am — Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference (GlobeNewswire)
- Nov 10, 7:25 am — Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System (GlobeNewswire)
- Oct 31, 7:25 am — Alterity Therapeutics: Appendix 4C - Q1 FY26 Quarterly Cash Flow Report (GlobeNewswire)
- Oct 9, 7:25 am — Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire)
- Oct 2, 7:35 am — Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire)
- Sep 30, 3:01 pm — Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434 (Insider Monkey)
NDAPR (News-Driven AI Prediction Revision) events for ATHE
No NDAPR events found.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest